A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

drug protocol number
D5160C00007
drug sponsor
AstraZeneca
drug study
AZD9291
drug trial site
KFSH&RC-R
drug status
Completed
drug phase